SavedAdd your journal

Journals / Erciyes Tıp Dergisi / 2013 / Cilt: 35 - Sayı: 2

Preterm infantta hidrokortizon tedavisine bağlı gelişen kardiak hipertrofi: Olgu sunumu

Cardiac hypertrophy due to hydrocortisone treatment in a preterm infant: A case report

Nahide ALTUĞ
Yusuf Ünal SARIKABADAYI
Uğur DİLMEN
Ömer ERDEVE
Şerife Suna OĞUZ
Pages
93–95
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The case reported here is the firstpreterm infant with cardiac hypertrophy due to hydrocortisoneadministration for treatment of chronic lung disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infants with chronic lung disease are at greater risk for pulmo-nary compromise in childhood.
📊
Key Findings & Data:A preterm infant,with a gestational age of 26 weeks, was admitted to the neonatalintensive care unit.
💡
Conclusion & Impact:The case reported here is the firstpreterm infant with cardiac hypertrophy due to hydrocortisoneadministration for treatment of chronic lung disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Infants with chronic lung disease are at greater risk for pulmo-nary compromise in childhood. Hydrocortisone has been stud-ied in the treatment of chronic lung disease. A preterm infant,with a gestational age of 26 weeks, was admitted to the neonatalintensive care unit. On the 28th postnatal day, the patient stillhad oxygen requirement (FiO2: 0.40) and hydrocortisone treat-ment was given for seven days. After the treatment the echocar-diography revealed a remarkable thickening of the left ventricleand interventricular septum. The case reported here is the firstpreterm infant with cardiac hypertrophy due to hydrocortisoneadministration for treatment of chronic lung disease.

Özet

Kronik akciğer hastalığı olan infantlar çocukluk çağında solunum fonksiyonlarının bozulması açısından büyük risk taşırlar. Hidrokortizon kronik akciğer hastalığının tedavisinde de kullanılmaktadır. Gestasyon haftası 26 olan preterm bir yenidoğana yenidoğan yoğun bakım ünitesindeki takibinde postnatal 28.günde oksijen ihtiyacı (FiO2: 0,40) olması nedeniyle hidrokortizon tedavisi yedi gün uygulandı. Tedavi sonrası kontrolekokardiyografisinde dikkate değer sol ventrikül ve interventriküler septum hipertrofisi saptandı. Rapor edilen bu vaka hidrokortizon kullanımına bağlı kardiyak hipertrofi gelişen ilk preterm infanttır.

🔖

Cite This Article

ALTUĞ, N., SARIKABADAYI, Y. Ü., DİLMEN, U., ERDEVE, Ö., OĞUZ, Ş. S. (2022). Preterm infantta hidrokortizon tedavisine bağlı gelişen kardiak hipertrofi: Olgu sunumu. Erciyes Tıp Dergisi, Cilt: 35 - Sayı: 2, 93–95. https://ajindex.com/articles/502381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. The Members of the National Institute of Child Health and Human Development Neonatal Research Network. Pediatrics 1993; 92(2): 191-6
  2. Bancalari E. Corticosteroids and neonatal chronic lung disease. Eur J Pediatr 1998; 157 Suppl 1: S31-37. [CrossRef] 3. Nye J. Postnatal corticosteroids in the treatment of chronic lung dis- ease in the preterm infant: past, present, and future. Neonatal Netw 2007; 26(5): 293-9. [CrossRef] 4. Werner JC, Sicard RE, Hansen TW, Solomon E, Cowett RM, Oh W. Hy- pertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysphasia. J Pediatr 1992; 120(2): 286-91. [CrossRef] 5. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: short-term gain, long-term pain? J Pediatr 2000; 137(1): 9-13. [CrossRef] 6. Ehrenkranz RA, Mercurio R. Bronchopulmonary dysplasia. In: Sinclair J, Bracken MB, editors. Effective care of the newborn infant. Oxford: Oxford University Press; 1992.p.399-24
  3. Scirè G, D’Anella G, Cristofori L, Mazzuca V, Cianfarani S. Marked left ventricular hypertrophy mimicking hypertrophic cardiomyopathy associated with steroid therapy for congenital adrenal hyperplasia. J Cardiovasc Med (Hagerstown) 2007; 8(6): 465-7. [CrossRef] 8. Conwell LS, Gray LM, Delbridge RG, Thomsett MJ, Batch JA. Revers- ible cardiomyopathy in paediatric Addison’s disease--a cautionary tale. J Pediatr Endocrinol Metab 2003; 16(8): 1191-5. [CrossRef] 9. Breitweser JA, Meyer RA, Sperling MA, Tsang RC, Kaplan S. Cardiac sep- tal hypertrophy in hyperinsulinemic infants. J Pediatr 1980; 96(3): 535-9. [CrossRef] 10. Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR, eds. The science and practice of pediatric cardioogy. Second edition. Baltimore: Williams & Wilkins, 1998.p.1851.